These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33769073)

  • 1. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
    Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
    Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
    Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
    Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
    Dudek AZ; Wang X; Gu L; Duong S; Stinchcombe TE; Kratzke R; Borghaei H; Vokes EE; Kindler HL
    Clin Lung Cancer; 2020 Nov; 21(6):553-561.e1. PubMed ID: 32727707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience.
    Sezgin Y; Karhan O; Ileri S; Ebinc S; Tunc S; Urakci Z
    J Coll Physicians Surg Pak; 2024 Aug; 34(8):904-909. PubMed ID: 39113507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
    J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
    Danese MD; Daumont M; Nwokeji E; Gleeson M; Penrod JR; Lubeck D
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1568. PubMed ID: 34698447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
    Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with 
Malignant Pleural Mesothelioma].
    Zeng X; Jiang Z; Duan J
    Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE; Fahmy ES
    Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
    Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
    Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
    Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
    Ziółkowska B; Cybulska-Stopa B; Papantoniou D; Suwiński R
    BMC Cancer; 2022 Apr; 22(1):432. PubMed ID: 35443624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
    Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.
    Canova S; Ceresoli GL; Grosso F; Zucali PA; Gelsomino F; Pasello G; Mencoboni M; Rulli E; Galli F; De Simone I; Carlucci L; De Angelis A; Belletti M; Bonomi M; D'Aveni A; Perrino M; Bono F; Cortinovis DL;
    ESMO Open; 2022 Dec; 7(6):100644. PubMed ID: 36463732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
    J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
    Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
    Nagata Y; Sawada R; Takashima A; Shoji H; Honma Y; Iwasa S; Amano K; Kato K; Hamaguchi T; Shimada Y; Saruta M; Boku N
    Jpn J Clin Oncol; 2019 Dec; 49(11):1004-1008. PubMed ID: 31287877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma.
    Meirson T; Pentimalli F; Cerza F; Baglio G; Gray SG; Correale P; Krstic-Demonacos M; Markel G; Giordano A; Bomze D; Mutti L
    JAMA Netw Open; 2022 Mar; 5(3):e221490. PubMed ID: 35262715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.